###begin article-title 0
A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 75 81 75 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(OPG) </italic>
The purpose of this study was to evaluate the role of osteoprotegerin gene (OPG) polymorphisms as genetic modifiers in the etiology of prostate cancer (PCa) and disease progression.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 129 137 129 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C </italic>
###xml 141 149 141 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 184 187 184 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG</italic>
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Three hundred and sixty one patients with PCa and 195 normal controls were enrolled in the study, and two genetic polymorphisms, 149 T/C and 950 T/C in the putative promoter region of OPG, were genotyped.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 99 101 99 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 123 131 123 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C </italic>
###xml 135 143 135 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 202 205 202 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TC </italic>
###xml 209 212 209 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TT </italic>
###xml 229 237 229 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 353 356 353 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TC </italic>
###xml 360 363 360 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TT </italic>
###xml 391 394 391 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CC </italic>
###xml 404 406 404 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 463 466 463 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TC </italic>
###xml 470 473 470 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TT </italic>
###xml 501 504 501 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CC </italic>
###xml 514 516 514 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 554 557 554 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CC </italic>
###xml 662 664 662 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T </italic>
###xml 678 690 678 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG 950 T/C </italic>
###xml 802 804 802 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 188 196 <span type="species:ncbi:9606">patients</span>
###xml 611 619 <span type="species:ncbi:9606">patients</span>
There was no significant difference in the genotype frequencies between PCa patients and controls (P = 0.939 and 0.294 for 149 T/C and 950 T/C polymorphisms, respectively). However, those patients with TC and TT genotypes in the 950 T/C polymorphism had a significantly increased risk of extraprostatic (age-adjusted odds ratio; aOR = 1.74 and 2.03 for TC and TT genotypes compared with the CC genotype, P = 0.028) and metastatic disease (aOR = 1.72 and 2.76 for TC and TT genotypes compared with the CC genotype, P = 0.009) compared with those with the CC genotype. In addition, analysis of the metastatic PCa patients (Stage D) showed that the presence of the T allele of the OPG 950 T/C polymorphism was an independent risk factor predicting survival by Cox proportional hazard regression analyses (P = 0.031).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 111 113 111 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 123 131 123 131 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 138 142 138 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
###xml 220 228 <span type="species:ncbi:9606">patients</span>
Progression of PCa may be influenced by an intrinsic genetic factor of the host's bone metabolism. The variant C allele of 950 T/C in the OPG promoter may play a major role as a genetic safe guard against progression in patients with PCa.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 153 154 153 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 653 657 653 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">IGF1</italic>
###xml 700 701 700 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 102 105 <span type="species:ncbi:9606">men</span>
Prostate cancer (PCa) has a very high proclivity for metastasizing to bone, with approximately 90% of men with advanced disease having skeletal lesions [1]. Bone is an abundant repository for immobilized growth factors. When osteoclasts absorb bone by secreting protons and proteases, these growth factors are released and provide fertile ground in which tumor cells can grow. Bone-derived growth factors and adhesive molecules secreted by tumor cells can cause modifications in the development and progression of metastatic cancer growth. Indeed, our recent investigation disclosed that a genetic polymorphism in the insulin-like growth factor I gene (IGF1) is a strong modifier of PCa progression [2]. Thus, genetic factors involved in the interaction between prostate cancer cells and normal host cells in the bone environment such as osteoclasts and osteoblasts may be a significant determinant in the progression, and bone metastasis, of prostate cancer.
###end p 11
###begin p 12
###xml 309 310 309 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 311 312 311 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 524 525 524 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 812 813 812 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 814 815 814 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
The receptor activator of nuclear factor-kappa B (RANK, also called tumor necrosis factor receptor super family member 11A; TNFRSF11A), its ligand, RANKL (also called TNF ligand super family member 11; TNFSF11), and osteoprotegerin (OPG, also called as TNFRSF11B) are the major regulators of bone metabolism [3,4]. RANKL is a cytokine produced by osteoblasts that stimulates osteoclast activity and inhibits osteoclast apoptosis through binding to its receptor, RANK, which is expressed on osteoclasts and their precursors [3]. OPG, which acts as an inhibitor of osteoclastogenesis by serving as a decoy receptor for RANKL, is a potent inhibitor of osteoclastic bone resorption and has been investigated as a potential therapeutic modality for the treatment of both osteoporosis and tumour-induced bone disease [3-6].
###end p 12
###begin p 13
###xml 29 33 29 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
###xml 180 181 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 216 220 216 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
###xml 320 321 320 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 464 465 464 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 466 467 466 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 632 636 632 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
###xml 23 28 <span type="species:ncbi:9606">human</span>
###xml 526 534 <span type="species:ncbi:9606">patients</span>
The promoter region of human OPG contains various putative transcription factor binding sites that may mediate the stimulation of OPG expression by different calciotropic factors [7]. Polymorphisms in this region of OPG may contribute to the genetic regulation of bone mass, as suggested by several recent publications [8-13]. Through the inhibition of osteoclast-genesis, OPG has been suggested to be an important modifier of bone metabolism and bone metastasis [3-6]. Consequently, in this study we used a cohort of 361 PCa patients and 195 male controls to investigate the hypothesis that polymorphisms in the promoter region of OPG may be genetic modifiers of the development and progression of PCa.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Subjects
###end title 15
###begin p 16
###xml 947 949 947 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 950 952 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1403 1404 1403 1404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 62 70 <span type="species:ncbi:9606">patients</span>
###xml 283 291 <span type="species:ncbi:9606">patients</span>
###xml 437 445 <span type="species:ncbi:9606">patients</span>
###xml 677 680 <span type="species:ncbi:9606">men</span>
###xml 1030 1038 <span type="species:ncbi:9606">patients</span>
###xml 1073 1081 <span type="species:ncbi:9606">patients</span>
A total of 556 native Japanese subjects consisting of 361 PCa patients and 195 male controls were enrolled in our study. Control subjects were selected randomly from a native Japanese population attending a medical check-up at our community hospitals in Akita prefecture. All of the patients with PCa were treated at the Akita University Medical Center and the Kyoto University Hospital from January 1991 to January 2006. All of the PCa patients were diagnosed histologically with specimens obtained from transrectal needle biopsy or transurethral resection of the prostate for voiding symptoms. The prostate specific antigen (PSA) levels of all the controls were measured and men with a PSA level of 4.0 ng/ml or more were omitted from the control group. The pathological grading and clinical stage of PCa were determined according to the Tumor-Node-Metastatic system, the Gleason's histological grading, and the modified Whitmore-Jewett system [14-16]. All pathological grading was based on needle biopsy specimens in stage B-D patients and surgical specimens in stage A patients. We categorized the tumor grading into 3 groups: a high grade group consisting of Gleason 8-10 or poorly differentiated adenocarcinoma, an intermediate grade group consisting of Gleason 5-7 or moderately differentiated adenocarcinoma and a low grade group consisting of Gleason 2-4 or well-differentiated adenocarcinoma [2]. The study was carried out in compliance with the Helsinki declaration and was approved by the institutional review board at Akita University School of Medicine. Written informed consent was obtained from all of the subjects in this study.
###end p 16
###begin title 17
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
OPG genotyping analysis
###end title 17
###begin p 18
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
###xml 168 176 168 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C </italic>
###xml 303 311 303 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 386 390 386 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
###xml 637 645 637 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C </italic>
###xml 649 657 649 657 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 734 735 734 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 775 783 775 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C </italic>
###xml 788 793 788 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XbaI </italic>
###xml 851 853 851 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 898 900 898 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T </italic>
###xml 968 976 968 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 979 986 979 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HincII </italic>
###xml 1036 1038 1036 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 1077 1079 1077 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T </italic>
OPG genotyping was analyzed by a polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method. Two DNA fragments spanning 178 bp containing the 149 T/C single nucleotide polymorphism (SNP, rs3134071, 1024 bp upstream of the translation initiation site) and 147 bp containing the 950 T/C SNP (rs2073617, 223 bp upstream of the translation initiation site) in the OPG 5' untranslated region were amplified from genomic DNA. The PCR primer sequences were 5'-GTAATCCATGAATGGGACCACACT-3' and 5'-ATCGGAGCTTCCTACGCGCTGA-3', and 5'-GGGGGATCCTTTCCGCCCCA-3' and 5'-GTATCGCCTGCCTTTGATCAGT-3' for the fragment containing the 149 T/C and 950 T/C SNPs, respectively. Each PCR reaction was performed as described previously [2]. Digestion of the fragment containing 149 T/C with XbaI resulted in two fragments of 129 and 49 bp containing the C allele, and a 178 bp fragment containing the T allele. On the other hand, digestion of the PCR products containing 950 T/C by HincII resulted in 2 fragments of 110 and 37 bp with the C allele, and a 147 bp fragment with the T allele. These genotypes were confirmed by an automated sequencer (ABI PRISM 310 Genetic Analyzer; GMI Inc, Ramsey, MN) with GENESCAN software (Applied Biosystems, Foster City, CA).
###end p 18
###begin title 19
Determination of the serum level of OPG
###end title 19
###begin p 20
###xml 56 64 <span type="species:ncbi:9606">patients</span>
The serum levels of OPG in 192 male controls and 66 PCa patients were determined using enzyme-linked immunosorbent assays (ELISA, R&D Systems, Minneapolis, MN) according to the manufacturer's protocol. This control group consisted of 192 healthy volunteers, who were recruited in Akita prefecture and whose serum PSA levels were less than 4.0 ng/dl.
###end p 20
###begin title 21
Statistical Analysis
###end title 21
###begin p 22
###xml 770 772 770 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T </italic>
###xml 851 853 851 853 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T </italic>
###xml 925 927 925 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TT</italic>
###xml 929 931 929 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TC</italic>
###xml 937 940 937 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CC </italic>
###xml 1546 1547 1546 1547 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 1750 1755 <span type="species:ncbi:9606">Human</span>
Hardy-Weinberg equilibrium analyses were performed to compare the observed genotype frequencies of each category with the expected ones using a chi-square test (degrees of freedom = 1). The frequency of each allele and the relationship between each genotype were analyzed by chi-square analysis. Possible significant differences in age and serum variables in each genotype-stratified group were assessed by two-way analysis of variance (ANOVA). The age-adjusted odds ratio (aOR) and 95% confidence interval (CI) for the relative risk of PCa and the relationship between the genotype distribution and the tumor grade or stage were determined by multivariate logistic regression analysis with the inclusion of the factor of age. In addition, the gene dosage effect of the T allele was assessed by modeling a linear effect on the log odds scale for each T allele in a multivariate logistic regression, for example the genotypes TT, TC, and CC were assigned the values "2," "1," and "0," respectively. Survival time was calculated from the date of prostate cancer diagnosis to the day of cancer-specific death, with deaths from other causes excluded. Cancer-specific survival was estimated using the Kaplan-Meier method and the differences in survival were tested using the log rank test. Hazard ratios (HRs) and 95% CIs for cancer death were assessed by the Cox proportional hazard regression model. All of the data were entered into an access database and analyzed using the Excel 2000 and SPSS (version 10.0J; SPSS, Inc.) software. A probability (P) of < 0.05 was considered to be statistically significant. The linkage disequilibrium between the two loci was analyzed with LDA software (Linkage Disequilibrium Analyzer, version 1.0, Chinese National Human Genome Center, Beijing, China).
###end p 22
###begin title 23
Results
###end title 23
###begin title 24
Subject Characteristics
###end title 24
###begin p 25
###xml 163 165 157 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 610 611 604 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
###xml 197 205 <span type="species:ncbi:9606">patients</span>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
###xml 436 444 <span type="species:ncbi:9606">patients</span>
###xml 498 506 <span type="species:ncbi:9606">patients</span>
The mean age +/- SD was 64.6 +/- 9.2 years for the controls and 66.8 +/- 10.0 for the PCa patients. The controls were significantly younger than the PCa patients (P = 0.042). There were 24 stage A patients whose PCa was diagnosed incidentally by specimens removed for Benign prostatic hyperplasia (BPH) treatment. By clinical findings, 184 and 56 patients with PCa were classified into stage B and C disease, respectively. In total, 97 patients were classified as having metastatic PCa; eleven PCa patients had clinical stage D1 disease, while 86 had clinical D2 disease judged by radiological studies. (Table 1).
###end p 25
###begin p 26
###xml 0 16 0 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Osteoprotegerin </italic>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
###xml 66 69 <span type="species:ncbi:9606">PCa</span>
Osteoprotegerin genotype frequencies in prostate cancer patients (PCa) and control males
###end p 26
###begin p 27
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 18 25 18 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 34 36 34 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 81 89 81 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C </italic>
###xml 93 100 93 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C</italic>
a Prostate cancer versus control, P = 0.939 and 0.294 by the chi-square test for 149 T/C and 950 T/C, respectively.
###end p 27
###begin p 28
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 54 58 54 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1a-b</sub>
###xml 59 60 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 61 62 61 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 75 79 75 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1c-2</sub>
###xml 80 81 80 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 82 83 82 83 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 96 99 96 99 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3&#8211;4</sub>
###xml 100 101 100 101 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0</sub>
###xml 102 104 102 104 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0 </sub>
###xml 119 122 119 122 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;4</sub>
###xml 123 124 123 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 125 129 125 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0&#8211;1 </sub>
###xml 133 136 133 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;4</sub>
###xml 137 140 137 140 <sub xmlns:xlink="http://www.w3.org/1999/xlink">0&#8211;1</sub>
###xml 141 142 141 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 176 183 176 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 208 210 208 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 255 263 255 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C </italic>
###xml 267 273 267 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950T/C</italic>
###xml 318 325 318 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 359 361 359 361 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 406 414 406 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C </italic>
###xml 418 424 418 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950T/C</italic>
###xml 154 157 <span type="species:ncbi:9606">PCa</span>
###xml 194 197 <span type="species:ncbi:9606">PCa</span>
###xml 340 343 <span type="species:ncbi:9606">PCa</span>
b According to the Whitmore-Jewett system. Stage A = T1a-bN0M0, Stage B = T1c-2N0M0, Stage C = T3-4N0M0 and Stage D = T1-4N1M0-1 or T1-4N0-1M1. Localized PCa (Stage A + B + C) versus Metastatic PCa (Stage D) P = 0.931 and 0.005 by the chi-square test for 149 T/C and 950T/C, respectively. Organ confined (Stage A + B) versus Extraprostatic PCa (Stage C + D), P = 0.346 and 0.021 by the chi-square test for 149 T/C and 950T/C, respectively.
###end p 28
###begin p 29
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 261 263 261 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 281 283 281 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 328 336 328 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C </italic>
###xml 340 347 340 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C</italic>
c Low grade = well-differentiated carcinoma (WHO) or Gleason score 2-4 carcinoma, Intermediate grade = moderately differentiated carcinoma (WHO) or Gleason score 5-7 carcinoma, High grade = poorly differentiated carcinoma (WHO) or Gleason score 8-10 carcinoma. C allele frequency, P = 0.884 and 0.520 by the chi-square test for 149 T/C and 950 T/C, respectively.
###end p 29
###begin title 30
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
###xml 26 29 <span type="species:ncbi:9606">PCa</span>
OPG genotypes and risk of PCa
###end title 30
###begin p 31
###xml 76 83 76 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C</italic>
###xml 85 92 85 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">209 G/A</italic>
###xml 98 106 98 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">245 T/G </italic>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 270 278 270 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C </italic>
###xml 352 359 352 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C</italic>
###xml 403 411 403 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C </italic>
###xml 507 515 507 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 615 617 615 617 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 809 817 809 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C </italic>
###xml 821 829 821 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 888 889 888 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 895 899 895 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
###xml 985 987 985 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1099 1106 1099 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C</italic>
###xml 1125 1132 1125 1132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C</italic>
###xml 1184 1191 1184 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C</italic>
###xml 1210 1217 1210 1217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C</italic>
###xml 1282 1286 1282 1286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
###xml 1398 1399 1398 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 1514 1516 1514 1516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1542 1546 1542 1546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T/C </italic>
###xml 1550 1558 1550 1558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 637 645 <span type="species:ncbi:9606">patients</span>
###xml 651 654 <span type="species:ncbi:9606">PCa</span>
###xml 846 849 <span type="species:ncbi:9606">PCa</span>
###xml 933 936 <span type="species:ncbi:9606">PCa</span>
###xml 1085 1088 <span type="species:ncbi:9606">PCa</span>
###xml 1089 1097 <span type="species:ncbi:9606">patients</span>
###xml 1261 1264 <span type="species:ncbi:9606">PCa</span>
###xml 1478 1486 <span type="species:ncbi:9606">patients</span>
###xml 1492 1495 <span type="species:ncbi:9606">PCa</span>
A recent report revealed that the OPG polymorphisms in the promoter region, 149 T/C, 209 G/A, and 245 T/G are in strong linkage disequilibrium [9]. These three polymorphisms have been shown to provide TGT or CAG haplotypes [9]; therefore we investigated the genotype of 149 T/C among these polymorphisms. In addition, we analyzed another polymorphism, 950 T/C, which is located 801 bp downstream of the 149 T/C polymorphism. There is no report showing any linkage disequilibrium between the polymorphism at 950 T/C and any other surrounding SNPs. We examined the linkage disequilibrium between these two loci. The r2 and D' value of the patients with PCa were 0.1163 and 0.6875, respectively. These results suggested that no tight linkage disequilibrium between the two loci was shown. The frequencies of the 149 T/C and 950 T/C genotypes in the PCa and control groups are shown in Table 1. The OPG genotype frequency in each group (PCa and control) was in Hardy-Weinberg equilibrium (P > 0.05, data not shown). No significant differences in the allele frequencies were found when the PCa patients (149 T/C; T:C = 0.87:0.13, 950 T/C; T:C = 0.60:0.40) were compared with the controls (149 T/C; T:C = 0.89:0.11, 950 T/C; T:C = 0.60:0.40). To evaluate the risk of PCa according to the OPG genotype, logistic regression analysis was conducted with an adjustment for age at the time of diagnosis (Table 1). No significant increased risk was observed among the different genotypes of patients with PCa and the controls (P = 0.939 and 0.294 for 149 T/C and 950 T/C polymorphisms, respectively).
###end p 31
###begin title 32
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
###xml 18 21 <span type="species:ncbi:9606">PCa</span>
OPG Genotypes and PCa disease status
###end title 32
###begin p 33
###xml 59 71 59 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG 149 T/C </italic>
###xml 75 83 75 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 157 165 157 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C </italic>
Next, we examined the association between the genotypes of OPG 149 T/C and 950 T/C and clinicopathological variables at the time of diagnosis. Regarding the 149 T/C polymorphism, no significant differences in the allele frequencies were found between low/intermediate and high grades or between low and high stages (data not shown).
###end p 33
###begin p 34
###xml 14 22 14 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 186 189 186 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CC </italic>
###xml 205 212 205 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950T/C </italic>
###xml 271 272 271 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 279 282 279 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TT </italic>
###xml 286 289 286 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TC </italic>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 459 461 459 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 620 622 620 622 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 763 765 763 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 781 782 781 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 807 810 807 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TT </italic>
###xml 951 954 951 954 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CC </italic>
###xml 970 971 970 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 983 985 983 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TT</italic>
###xml 987 989 987 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TC</italic>
###xml 995 998 995 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CC </italic>
###xml 1086 1088 1086 1088 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T </italic>
###xml 1182 1184 1182 1184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1253 1255 1253 1255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1438 1440 1438 1440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
###xml 505 508 <span type="species:ncbi:9606">PCa</span>
###xml 509 517 <span type="species:ncbi:9606">patients</span>
###xml 574 577 <span type="species:ncbi:9606">PCa</span>
###xml 578 586 <span type="species:ncbi:9606">patients</span>
###xml 658 661 <span type="species:ncbi:9606">PCa</span>
###xml 662 670 <span type="species:ncbi:9606">patients</span>
###xml 723 726 <span type="species:ncbi:9606">PCa</span>
###xml 727 735 <span type="species:ncbi:9606">patients</span>
###xml 785 788 <span type="species:ncbi:9606">PCa</span>
###xml 789 797 <span type="species:ncbi:9606">patients</span>
###xml 933 941 <span type="species:ncbi:9606">patients</span>
Regarding the 950 T/C polymorphism, no significant differences in the allele frequencies were found between the low/intermediate and high grades (Table 1). However, the frequency of the CC genotype in the 950T/C polymorphism decreased as the tumor stage increased (Table 1). The TT and TC genotypes were more frequently observed in patients with tumors of a higher stage than those of a lower stage (Table 1). A significant difference in the frequency of the C allele was found between the organ-confined PCa patients (stage A and B; T:C = 0.57:0.43) and the extraprostatic PCa patients (stage C and D; T:C = 0.65:0.35, P = 0.021), and between the localized PCa patients (stage A, B, and C; T:C = 0.57:0.43) and metastatic PCa patients (stage D; T:C = 0.69:0.31, P = 0.005) (Table 1). PCa patients with the TT genotype had a 2.76-fold and 2.03-fold increased risk of metastatic and extraprostatic diseases, respectively, compared to patients with the CC genotype (Table 2). When the TT, TC, and CC genotypes were assigned the values "2," "1," and "0", respectively, the presence of the T allele significantly increased the risk of metastatic disease (aOR = 1.65, 95%CI = 1.17-2.33, P = 0.005) and extra prostatic disease (aOR = 1.37, 95%CI = 1.01-1.84, P = 0.04) with a gene-dosage effect. However, no significant difference in the genotype frequency was found among the three subgroups of tumor grade (low, intermediate, and high grade; P = 0.253).
###end p 34
###begin p 35
###xml 42 65 42 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Osteoprotegerin950 T/C </italic>
Age-adjusted odds ratios according to the Osteoprotegerin950 T/C genotype
###end p 35
###begin p 36
a These data were adjusted for age.
###end p 36
###begin p 37
b The tumor stage and grade systems are the same as those in Table 1.
###end p 37
###begin title 38
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
###xml 0 7 <span type="species:ncbi:9606">Patient</span>
###xml 34 37 <span type="species:ncbi:9606">PCa</span>
Patient prognosis with metastatic PCa (Stage D) and OPG genotypes
###end title 38
###begin p 39
###xml 73 85 73 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG 149 T/C </italic>
###xml 93 101 93 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 317 325 317 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C </italic>
###xml 501 509 501 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 658 660 658 660 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CC</italic>
###xml 662 664 662 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TC</italic>
###xml 670 673 670 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TT </italic>
###xml 690 691 690 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 797 800 797 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CC </italic>
###xml 851 854 851 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TC </italic>
###xml 857 860 857 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TT </italic>
###xml 895 898 895 898 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TC </italic>
###xml 902 905 902 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TT </italic>
###xml 933 936 933 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CC </italic>
###xml 946 948 946 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 988 989 988 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1084 1086 1084 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T </italic>
###xml 1100 1108 1100 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG 950 </italic>
###xml 1219 1221 1219 1221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1236 1237 1236 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 1255 1257 1255 1257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 1311 1320 1311 1320 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C allele </italic>
###xml 1323 1331 1323 1331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 1338 1342 1338 1342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
###xml 138 141 <span type="species:ncbi:9606">PCa</span>
###xml 191 199 <span type="species:ncbi:9606">patients</span>
###xml 216 219 <span type="species:ncbi:9606">PCa</span>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
###xml 443 451 <span type="species:ncbi:9606">patients</span>
###xml 779 787 <span type="species:ncbi:9606">patients</span>
###xml 833 841 <span type="species:ncbi:9606">patients</span>
###xml 1410 1413 <span type="species:ncbi:9606">PCa</span>
Next, we investigated the association between the clinical variables and OPG 149 T/C and the 950 T/C genotype in patients with metastatic PCa (Stage D) after the initial diagnosis. Among the patients with metastatic PCa, the outcome and the serum variables of 90 patients were available for this study. Regarding the 149 T/C polymorphism, no significant differences in the allele frequencies were found between the clinical variables of these patients and the genotype (data not shown). Regarding the 950 T/C polymorphism, age, initial PSA, hemoglobin, alkaline phosphatase (ALP), and the biopsy histological grade were not significantly different among the CC, TC, and TT genotypes (Table 3). However, although the difference was not significant, the cause-specific survival of patients with the CC genotype was better than that of patients with the TC or TT genotype (OR = 2.938 and 3.018 for TC and TT genotypes compared with the CC genotype, P = 0.087 and 0.082, respectively. Figure 1). In addition, according to the multivariate Cox proportional hazard regression analyses, the T allele of the OPG 950 T/C polymorphism was an independent risk factor predicting survival with HRs of 2.157 (95% CI = 1.072 - 4.341, P = 0.031, Table 4) compared to the C allele. These results also suggested that the variant C allele of 950 T/C in the OPG promoter may have some protective effect against the progression of PCa.
###end p 39
###begin p 40
###xml 105 116 105 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG 950T/C </italic>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Association between the clinical variables of patients with metastatic prostate cancer (Stage D) and the OPG 950T/C genotype
###end p 40
###begin p 41
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">1</sup>
1Values represent the median (inter-quartile range).
###end p 41
###begin p 42
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
2Values represent the number (%).
###end p 42
###begin p 43
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3</sup>
3Analysis of variance or chi-square test.
###end p 43
###begin p 44
Abbreviations: PSA; prostate specific antigen, ALP, alkaline phosphatase.
###end p 44
###begin p 45
###xml 138 146 <span type="species:ncbi:9606">patients</span>
Multivariate Cox proportional hazard regression analysis of predicting factors for cancer-specific survival of metastatic prostate cancer patients (Stage D)
###end p 45
###begin p 46
###xml 125 128 125 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG</italic>
###xml 130 162 130 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">osteoprotegerin 950 T/C genotype</italic>
Abbreviations: HR; hazard ratio, 95% CI; 95% confidence interval, PSA; prostate specific antigen, ALP, alkaline phosphatase, OPG; osteoprotegerin 950 T/C genotype
###end p 46
###begin p 47
###xml 55 67 55 67 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C OPG </italic>
###xml 0 75 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Comparison of the outcome of patients with PCa and the <italic>950 T/C OPG </italic>genotype</bold>
###xml 145 148 145 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CC </italic>
###xml 168 171 168 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TC </italic>
###xml 175 178 175 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TT </italic>
###xml 219 221 219 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 29 37 <span type="species:ncbi:9606">patients</span>
###xml 43 46 <span type="species:ncbi:9606">PCa</span>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
Comparison of the outcome of patients with PCa and the 950 T/C OPG genotype. The differences in cause-specific survival of the patients with the CC genotype versus the TC and TT genotypes were an OR of 2.938 and 3.018 (P = 0.087 and 0.082, respectively).
###end p 47
###begin title 48
###xml 57 65 <span type="species:ncbi:9606">patients</span>
###xml 71 74 <span type="species:ncbi:9606">PCa</span>
Serum level and genotypes of OPG in healthy controls and patients with PCa
###end title 48
###begin p 49
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
###xml 166 174 166 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C </italic>
###xml 178 186 178 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 430 432 428 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 494 496 490 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 561 563 555 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 715 717 709 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 728 731 722 725 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-22</sup>
###xml 841 843 835 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 854 857 848 851 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-13</sup>
###xml 1036 1048 1030 1042 <italic xmlns:xlink="http://www.w3.org/1999/xlink">the 149 T/C </italic>
###xml 1056 1064 1050 1058 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 1162 1164 1156 1158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 226 229 <span type="species:ncbi:9606">PCa</span>
###xml 230 238 <span type="species:ncbi:9606">patients</span>
###xml 346 354 <span type="species:ncbi:9606">patients</span>
###xml 370 373 <span type="species:ncbi:9606">PCa</span>
###xml 400 403 <span type="species:ncbi:9606">PCa</span>
###xml 641 649 <span type="species:ncbi:9606">patients</span>
###xml 655 658 <span type="species:ncbi:9606">PCa</span>
###xml 758 766 <span type="species:ncbi:9606">patients</span>
###xml 772 775 <span type="species:ncbi:9606">PCa</span>
###xml 918 926 <span type="species:ncbi:9606">patients</span>
###xml 932 935 <span type="species:ncbi:9606">PCa</span>
###xml 1098 1106 <span type="species:ncbi:9606">patients</span>
###xml 1112 1115 <span type="species:ncbi:9606">PCa</span>
We hypothesized that the promoter activity of OPG would reflect the OPG serum level. Consequently, we investigated the association between the serum level of OPG and 149 T/C and 950 T/C genotypes in 192 normal controls and 74 PCa patients whose serum was available for this study. The mean serum levels of OPG for all of the normal controls, the patients with localized PCa and those with metastatic PCa were 52.6 +/- 19.7 pg/ml (n = 192; median 48.7, quartile 39.3-60.4), 84.2 +/- 32.7 pg/ml (n = 66; median 82.1, quartile 64.4-101), and 122.2 +/- 34.4 pg/ml (n = 8; median 132, quartile 105-141.7), respectively. The serum level of OPG in patients with PCa was significantly higher than that of healthy controls (P = 3.50 x 10-22); however, the age of the patients with PCa was also significantly higher than that of the healthy controls (P = 1.47 x 10-13). Comparison of the OPG serum level in healthy controls and patients with PCa was therefore not conclusive. We also investigated the relationship between the OPG serum level and the 149 T/C and the 950 T/C genotypes in healthy controls and patients with PCa; no significant association was found (Figure 2A).
###end p 49
###begin p 50
###xml 0 62 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The serum OPG levels in healthy controls and patients with PCa</bold>
###xml 111 119 111 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 59 62 <span type="species:ncbi:9606">PCa</span>
###xml 169 172 <span type="species:ncbi:9606">PCa</span>
###xml 173 181 <span type="species:ncbi:9606">patients</span>
###xml 291 299 <span type="species:ncbi:9606">patients</span>
###xml 305 308 <span type="species:ncbi:9606">PCa</span>
The serum OPG levels in healthy controls and patients with PCa. (A) Comparison of the serum OPG levels and the 950 T/C genotype in 192 healthy controls and 66 localized PCa patients. (B) Comparison of the serum OPG level by age and disease status (stage B, C, and D) in healthy controls and patients with PCa. *Age represents mean +/- standard deviation.
###end p 50
###begin title 51
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 80 83 <span type="species:ncbi:9606">PCa</span>
OPG serum level by age and disease status in healthy controls and patients with PCa
###end title 51
###begin p 52
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 635 637 635 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 677 678 677 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
###xml 133 136 <span type="species:ncbi:9606">PCa</span>
###xml 248 256 <span type="species:ncbi:9606">patients</span>
###xml 277 280 <span type="species:ncbi:9606">PCa</span>
###xml 427 435 <span type="species:ncbi:9606">patients</span>
###xml 456 459 <span type="species:ncbi:9606">PCa</span>
###xml 499 507 <span type="species:ncbi:9606">patients</span>
###xml 524 527 <span type="species:ncbi:9606">PCa</span>
###xml 577 585 <span type="species:ncbi:9606">patients</span>
###xml 792 795 <span type="species:ncbi:9606">PCa</span>
We investigated the association between the OPG serum level and the age and disease status of the healthy controls and patients with PCa. We detected a significant increase in the serum levels of OPG with age in the healthy controls, as well as in patients with non-metastatic PCa (stage B and C, Figure 2B). In addition, there was no significant difference between the age-matched serum OPG levels of the healthy controls and patients with non-metastatic PCa. The serum level of OPG in age-matched patients with metastatic PCa (stage D2) was significantly higher than that of patients without metastatic disease and healthy controls (P = 0.012 and 0.005, respectively. Figure 2). These results suggest that aging and bone metastasis have a major effect on the serum level of OPG rather than PCa.
###end p 52
###begin title 53
Discussion and conclusion
###end title 53
###begin p 54
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 517 518 517 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 519 520 519 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 594 602 594 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">149 T/C </italic>
###xml 737 739 737 739 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 753 761 753 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 781 785 781 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
###xml 867 869 867 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 1082 1083 1082 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1167 1169 1167 1169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T </italic>
###xml 1187 1195 1187 1195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 1275 1277 1275 1277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 1332 1334 1332 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1357 1365 1357 1365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 1474 1478 1474 1478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
###xml 1537 1541 1537 1541 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T/C </italic>
###xml 1555 1563 1555 1563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 676 684 <span type="species:ncbi:9606">patients</span>
###xml 690 693 <span type="species:ncbi:9606">PCa</span>
###xml 832 835 <span type="species:ncbi:9606">PCa</span>
###xml 924 932 <span type="species:ncbi:9606">patients</span>
###xml 978 981 <span type="species:ncbi:9606">PCa</span>
###xml 1002 1010 <span type="species:ncbi:9606">patients</span>
###xml 1059 1062 <span type="species:ncbi:9606">PCa</span>
###xml 1126 1129 <span type="species:ncbi:9606">PCa</span>
###xml 1130 1138 <span type="species:ncbi:9606">patients</span>
###xml 1670 1673 <span type="species:ncbi:9606">PCa</span>
Over a hundred years ago, Stephen Paget enunciated the "seed and soil" hypothesis in which seeds of metastatic cancer cells preferentially settle in the soil of the bone matrix, where there is an abundant repository for immobilized growth factor [17]. In this study, we hypothesized that the host's bone metabolism may modify disease development and progression. Among many factors that play important roles in bone metabolism, OPG is a major factor in osteoclastgenesis and is known as osteoclast inhibitory factor [3,4]. In this study, no significant differences in the allele frequencies of 149 T/C polymorphism were found in the clinical and pathological variables in the patients with PCa. However, this study demonstrated that the C allele of the 950 T/C polymorphism in the OPG promoter region decreased the risk of advanced PCa with a gene-dosage effect. The C allele was found at a significantly lower frequency in patients with metastatic (stage D) and extraprostatic PCa (stage C+D) than in patients with localized (stage A+B+C) and organ confined PCa (stage A+B) (Table 2). In addition, the analysis of metastatic PCa patients (Stage D) revealed that the T allele of the OPG 950 T/C polymorphism was an independent risk factor predicting survival compared to the C allele by Cox proportional hazard regression analyses (P = 0.031). Although the 950 T/C is not a putative transcription factor binding site, an altered secondary structure may cause differences in OPG mRNA expression. Therefore, these results suggest that the T/C allele of the 950 T/C polymorphism functions as a modifier of OPG expression and has some effect on metastasis and the spread of PCa cells. Alternatively, it is possible that this polymorphism is in linkage disequilibrium with other SNP(s) that alters OPG function.
###end p 54
###begin p 55
###xml 51 52 51 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 78 86 78 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 239 241 239 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T </italic>
###xml 255 263 255 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 407 410 407 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CC </italic>
###xml 426 434 426 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 553 556 553 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TT </italic>
###xml 604 607 604 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TC </italic>
###xml 611 614 611 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CC </italic>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 805 807 805 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 814 822 814 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 911 913 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 914 916 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
Although conflicting results have been documented [8-10], the genotype of the 950 T/C polymorphism has been reported to be independently associated with a subset of osteoporosis or bone marrow density (BMD). Vidal et al. reported that the T allele of the 950 T/C polymorphism was associated with low BMD, although statistical significance was not reached [11]. Arko et al. also revealed that the homozygote CC genotype of the 950 T/C polymorphism had the highest BMD of all of the anatomical sites [12]. In addition, Ohmori et al. demonstrated that the TT genotype had a significantly lower BMD than the TC and CC genotypes by parametric and non parametric analysis [13]. Interestingly, they used healthy DNA samples from the same prefecture, Akita in Japan. In addition, recent studies reported that the C allele 950 T/C polymorphism contributed to calcification of the vascular system and the osseous tissue [18-20].
###end p 55
###begin p 56
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 686 688 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 689 691 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 862 864 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1147 1151 1147 1151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
###xml 1233 1235 1233 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1427 1435 1427 1435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">950 T/C </italic>
###xml 1486 1490 1486 1490 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG </italic>
###xml 225 233 <span type="species:ncbi:9606">patients</span>
###xml 239 242 <span type="species:ncbi:9606">PCa</span>
###xml 295 303 <span type="species:ncbi:9606">patients</span>
###xml 1001 1009 <span type="species:ncbi:9606">patients</span>
###xml 1027 1035 <span type="species:ncbi:9606">patients</span>
###xml 1190 1195 <span type="species:ncbi:10090">mouse</span>
###xml 1227 1231 <span type="species:ncbi:10090">mice</span>
Instead of measuring the expression level of OPG in the bone tissues, we compared the serum level of OPG for each of the genotypes; however, there was no difference among these genotypes either in the healthy controls or the patients with PCa. The serum level of OPG was significantly higher in patients with bone metastasis than those without bone metastasis; this is in agreement with previous reports [21-23]. In addition, we found that the serum level of OPG in the older individuals was significantly higher than that of the younger ones. Our results support previous findings that the serum levels of OPG increase with age in relatively large healthy adult Caucasian populations [24,25]. In contrast, Lipton et al. reported that serum OPG values did not differ significantly by age, although they analyzed male and female healthy control samples together [26]. The relationship between age and serum OPG warrants further investigation because healthy controls have a tendency to be younger than patients with cancer, and patients with advanced stage disease are usually older than those with early stage cancer. Cao et al. demonstrated that OPG mRNA levels in bones of the adult male mouse were lower than those in young mice [27]. These results indicate that the serum levels of OPG do not precisely reflect the expression profile or OPG level in the local bone environment. Therefore, we could not confirm whether each 950 T/C polymorphism genotype had a considerable effect on OPG expression.
###end p 56
###begin p 57
###xml 19 31 19 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">OPG 950 T/C </italic>
###xml 144 146 144 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C </italic>
###xml 86 89 <span type="species:ncbi:9606">PCa</span>
###xml 102 105 <span type="species:ncbi:9606">men</span>
###xml 244 252 <span type="species:ncbi:9606">patients</span>
###xml 258 261 <span type="species:ncbi:9606">PCa</span>
###xml 514 517 <span type="species:ncbi:9606">PCa</span>
In conclusion, the OPG 950 T/C polymorphism was not associated with susceptibility to PCa in Japanese men. However, the presence of the variant C allele may have a considerable protective effect against metastasis or advanced disease status in patients with PCa. This effect is not associated with a biologically less aggressive (low grade) tumor, but may be due to the modification of cancer progression and metastasis through the host's bone metabolism. In order to clarify the role of OPG in the progression of PCa, further molecular studies are warranted.
###end p 57
###begin title 58
Competing interests
###end title 58
###begin p 59
The authors declare that they have no competing interests.
###end p 59
###begin title 60
Authors' contributions
###end title 60
###begin p 61
FN, TY, NT, TK, and SI carried out the molecular genetics studies, participated in the sequence alignment, drafted the manuscript. TI and MS performed the ELISA. ZM, YH, and SS performed the statistical analysis. TY, OO, and TH conceived of the study, and participated in its design and coordination. All authors read and approved the final manuscript.
###end p 61
###begin title 62
Pre-publication history
###end title 62
###begin p 63
The pre-publication history for this paper can be accessed here:
###end p 63
###begin p 64

###end p 64
###begin title 65
Acknowledgements
###end title 65
###begin p 66
We thank Ms. Yoko Mitobe and Yukiko Sugiyama for their technical assistance. This work was partly supported by Kobayashi Institute for Innovative Cancer Chemotherapy, the Shimadzu Science Foundation, the Sagawa Foundation for Promotion of Cancer Research, Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, and the COE program of the Ministry of Education, Culture, Sports, Science and Technology, Japan.
###end p 66
###begin article-title 67
Mechanisms of bone metastasis
###end article-title 67
###begin article-title 68
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Impact of IGF-I and CYP19 gene polymorphisms on the survival of patients with metastatic prostate cancer
###end article-title 68
###begin article-title 69
RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis
###end article-title 69
###begin article-title 70
Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases
###end article-title 70
###begin article-title 71
Osteoprotegerin in prostate cancer bone metastasis
###end article-title 71
###begin article-title 72
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone
###end article-title 72
###begin article-title 73
###xml 50 55 <span type="species:ncbi:9606">human</span>
Cloning and characterization of the gene encoding human osteoprotegerin/osteoclastogenesis-inhibitory factor
###end article-title 73
###begin article-title 74
Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures
###end article-title 74
###begin article-title 75
###xml 95 100 <span type="species:ncbi:9606">women</span>
###xml 109 112 <span type="species:ncbi:9606">men</span>
Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men
###end article-title 75
###begin article-title 76
###xml 114 119 <span type="species:ncbi:9606">women</span>
No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women
###end article-title 76
###begin article-title 77
###xml 67 72 <span type="species:ncbi:9606">women</span>
TNFRSF11B gene variants and bone mineral density in postmenopausal women in Malta
###end article-title 77
###begin article-title 78
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis
###end article-title 78
###begin article-title 79
###xml 72 77 <span type="species:ncbi:9606">human</span>
Linkage and association analyses of the osteoprotegerin gene locus with human osteoporosis
###end article-title 79
###begin article-title 80
From Prostate
###end article-title 80
###begin article-title 81
From Histological grading and clinical staging of prostate carcinoma
###end article-title 81
###begin article-title 82
Prostate Cancer
###end article-title 82
###begin article-title 83
The distribution of secondary growths in cancer of the breast
###end article-title 83
###begin article-title 84
###xml 94 97 <span type="species:ncbi:9606">men</span>
Association between osteoprotegerin gene polymorphism and coronary artery disease in Japanese men
###end article-title 84
###begin article-title 85
###xml 63 68 <span type="species:ncbi:9606">human</span>
A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function
###end article-title 85
###begin article-title 86
###xml 38 41 <span type="species:ncbi:9606">men</span>
Osteoprotegerin gene polymorphisms in men with coronary artery disease
###end article-title 86
###begin article-title 87
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Serum osteoprotegerin levels are increased in patients with advanced prostate cancer
###end article-title 87
###begin article-title 88
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications
###end article-title 88
###begin article-title 89
###xml 112 120 <span type="species:ncbi:9606">patients</span>
Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer
###end article-title 89
###begin article-title 90
Serum levels of osteoprotegerin increase with age in healthy adult population
###end article-title 90
###begin article-title 91
Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover
###end article-title 91
###begin article-title 92
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Serum osteoprotegerin levels in healthy controls and cancer patients
###end article-title 92
###begin article-title 93
###xml 82 86 <span type="species:ncbi:10090">mice</span>
Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice
###end article-title 93

